The estimated Net Worth of J Matthew Singleton is at least $1.11 Million dollars as of 21 August 2024. Mr. Singleton owns over 5,700 units of Viking Therapeutics Inc stock worth over $924,616 and over the last 10 years he sold VKTX stock worth over $0. In addition, he makes $182,466 as Independent Director at Viking Therapeutics Inc.
Sign up
Mr. Singleton VKTX stock SEC Form 4 insiders trading
J has made over 4 trades of the Viking Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,700 units of VKTX stock worth $6,783 on 21 August 2024.
The largest trade he's ever made was exercising 20,786 units of Viking Therapeutics Inc stock on 14 August 2024 worth over $166,288. On average, J trades about 3,466 units every 152 days since 2015. As of 21 August 2024 he still owns at least 15,200 units of Viking Therapeutics Inc stock.
You can see the complete history of Mr. Singleton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
J. Matthew Singleton biography
J. Matthew Singleton CPA serves as Independent Director of the Company. In October 2011, Mr. Singleton has served as a member of our Board since May 2014. In October 2011, Mr. Singleton retired from his position as Executive Vice President and Chief Financial Officer of CitationAir (formerly CitationShares LLC), a privately held jet services company wholly-owned by Textron Inc., a public industrial conglomerate. He had served in this position since 2000. Mr. Singleton has extensive financial, accounting and transactional experience, including through his role as Managing Director, Executive Vice President and Chief Administrative Officer of CIBC World Markets, an investment banking company, for 20 years, from 1974 to 1994, at Arthur Andersen & Co., a public accounting firm, including as Partner-in-Charge of the Metro New York Audit and Business Advisory Practice, and as a Practice Fellow at the Financial Accounting Standards Board, a private organization responsible for establishing financial accounting reporting standards. From 2003 until 2014, Mr. Singleton served as a director of Cubist Pharmaceuticals Inc., and as Audit Committee Chair beginning in 2004. Mr. Singleton previously served as an independent director of Salomon Reinvestment Company Inc., a privately held investment services company. Mr. Singleton received an AB in Economics from Princeton University and his MBA from New York University with a focus in Accounting.
What is the salary of J Singleton?
As the Independent Director of Viking Therapeutics Inc, the total compensation of J Singleton at Viking Therapeutics Inc is $182,466. There are 6 executives at Viking Therapeutics Inc getting paid more, with Brian Lian having the highest compensation of $3,512,120.
How old is J Singleton?
J Singleton is 67, he's been the Independent Director of Viking Therapeutics Inc since 2014. There are no older and 9 younger executives at Viking Therapeutics Inc.
What's J Singleton's mailing address?
J's mailing address filed with the SEC is C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121.
Insiders trading at Viking Therapeutics Inc
Over the last 10 years, insiders at Viking Therapeutics Inc have traded over $46,107,976 worth of Viking Therapeutics Inc stock and bought 199,715 units worth $855,627 . The most active insiders traders include Brian Lian, Charles A Jr Rowland, and Marianna Mancini. On average, Viking Therapeutics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $4,137,170. The most recent stock trade was executed by Brian Lian on 21 August 2024, trading 1,000 units of VKTX stock currently worth $7,770.
What does Viking Therapeutics Inc's logo look like?
Complete history of Mr. Singleton stock trades at Viking Therapeutics Inc
Viking Therapeutics Inc executives and stock owners
Viking Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brian Lian,
President, Chief Executive Officer, Director -
Dr. Brian Lian Ph.D.,
Pres, CEO & Director -
Michael Morneau,
Vice President - Finance and Administration -
S. Kathy Rouan,
Independent Director -
Lawson Macartney,
Independent Chairman of the Board -
Charles Rowland,
Independent Director -
J. Matthew Singleton,
Independent Director -
Matthew Foehr,
Director -
Greg Zante,
Senior Vice President - Finance, IR Contact Officer -
Michael Morneau,
VP of Fin. & Admin. -
Marianne Mancini,
Chief Operating Officer -
Gregory S. Zante,
Chief Financial Officer -
Pharmaceuticals Inc Ligand,
10% owner -
Stephen W Webster,
Director -
Rochelle Hanley,
Chief Medical Officer -
Hiroko Masamune,
Chief Development Officer -
Marianna Mancini,
Chief Operating Officer -
Michael Dinerman,
Chief Operating Officer